scholarly journals EVIDENCE-BASED TREATMENT OF REFRACTORY CHRONIC URTICARIA

2014 ◽  
Vol 11 (6) ◽  
pp. 63-69
Author(s):  
I V Danilycheva
Keyword(s):  
Chronic Urticaria ◽  
Signs And Symptoms ◽  
Chronic Spontaneous Urticaria ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Beneficial Effects ◽  
Results Of Treatment ◽  
Lack Of Control ◽  
Mechanisms Of Development

Despite advances in understanding of mechanisms of development of hives, many patients and their physicians remain unsatisfied results of treatment, lack of control of the disease. Now treatment of patients with the chronic urticarial has landmark character. The new indication for omalizumab was registered in Russia in 2014, giving the chance to achieve the control on a refractory form of urticaria. Omalizumab demonstrated rapid and beneficial effects on the signs and symptoms of chronic spontaneous urticaria torpid to H1blockers in the numerous studies.

scholarly journals Improving smoking cessation after myocardial infarction by systematically implementing evidence-based treatment methods

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Margret Leosdottir ◽  
Sanne Wärjerstam ◽  
Halldora Ögmundsdottir Michelsen ◽  
Mona Schlyter ◽  
Emma Hag ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Smoking Cessation ◽  
Prognostic Value ◽  
Routine Practice ◽  
Evidence Based ◽  
Post Discharge ◽  
Evidence Based Treatment ◽  
Beneficial Effects ◽  
Before And After ◽  
Secondary Outcomes

AbstractWe compared the odds of smoking cessation at 2-months post-myocardial infarction (MI), before and after implementing routines optimizing use of evidence-based smoking cessation methods, with start during admission. The following routines were implemented at six Swedish hospitals: cardiac rehabilitation nurses offering smokers consultation during admission, optimizing nicotine replacement therapy and varenicline prescription, and contacting patients by telephone during the 1st week post-discharge. Using logistic regression, odds for smoking cessation at 2-months before (n smokers/n admitted = 188/601) and after (n = 195/632) routine implementation were compared. Secondary outcomes included adherence to implemented routines and assessing the prognostic value of each routine on smoking cessation. After implementation, a larger proportion of smokers (65% vs. 54%) were abstinent at 2-months (OR 1.60 [1.04–2.48]). Including only those counselled during admission (n = 98), 74% were abstinent (2.50 [1.42–4.41]). After implementation, patients were more often counselled during admission (50% vs. 6%, p < 0.001), prescribed varenicline (23% vs. 7%, p < 0.001), and contacted by telephone post-discharge (18% vs. 2%, p < 0.001). Being contacted by telephone post-discharge (adjusted OR 2.74 [1.02–7.35]) and prescribed varenicline (adjusted OR 0.39 [0.19–0.83]) predicted smoking cessation at 2-months. In conclusion, readily available methods for aiding smoking cessation can be implemented effectively in routine practice, with beneficial effects for post-MI patients.

scholarly journals Chronic spontaneous urticaria: news about problem and treatment (literature review)

2019 ◽  
Vol 2 (26) ◽  
pp. 15-20
Author(s):  
L. S. Kruglova
Keyword(s):  
Partial Response ◽  
Literature Review ◽  
Effective Dose ◽  
Chronic Urticaria ◽  
Large Percentage ◽  
Chronic Spontaneous Urticaria ◽  
H1 Receptor ◽  
Treatment Results ◽  
Receptor Blockers ◽  
Mechanisms Of Development

Despite advances in understanding the mechanisms of development of chronic urticaria, in a large percentage of cases there are unsatisfied treatment results, there is no possibility of controlling the disease. Currently, the treatment of patients with chronic urticaria is of a staged nature. In 2014, omalizumab was registered in Russia for extended indications, which makes it possible to achieve control of the refractory form of chronic spontaneous urticaria. The article presents data on the effectiveness and safety of omalizumab. According to the results of numerous studies, omalizumab showed a quick and pronounced effect in the treatment of patients with chronic spontaneous urticaria who do not respond to therapy with H1-receptor blockers. The issues of effective dose, safety and tolerability of the therapy, timing of evaluating the effectiveness, duration of the course and tactics of managing patients with a partial response or lack of response were considered.

scholarly journals Comparing rLH with hMG in embryo transfers at the stage of blastocyst and pregnancy outcomes in poor responders

2021 ◽  
Vol 38 (4) ◽  
pp. 474-477
Author(s):  
Nur DOKUZEYLÜL GÜNGÖR ◽  
Arzu YURCİ ◽  
Tuğba GÜRBÜZ ◽  
Kağan GÜNGÖR
Keyword(s):  
Patient Group ◽  
Clinical Pregnancy ◽  
Poor Responders ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Beneficial Effects ◽  
Cumulus Oophorus ◽  
Significant Difference ◽  
The Mean ◽  
Antagonist Protocol

Despite showing the beneficial effects of adding LH activity to FSH, based on the pregnancy rate (PR) in patients in the previous studies, no studies have been done to compare two different gonadotrophin preparations with activity of LH in the same group of poor responders. The present study was a single-center retrospective one conducted in January 2015 - December 2019 among 30 women under 39 years old who had reduced ovarian reserve and underwent ICSI cycles. The same patient group received rFSH combined with hMG or rLH. The ovarian stimulation cycle began on the second day of the menstrual cycle, and the initial doses of gonadotrophin were 225 IU/day rFSH in addition to 75 IU/day hMG or 75 IU/day rLH. In all cycles, a flexible antagonist protocol was used. Adding rLH significantly increased the mean number of MII oocytes and cumulus oophorus complex (COC) (p < 0.001). There was no significant difference between poor responders treated with rLH or with hMG in terms of blastocyst transfer, implantation rates and clinical pregnancy rates (p>0.05). There should be further studies to confirm the better effect of rLH addition to rFSH than hMG in young poor responders. Interventions for poor responders obviously need large, randomized studies which were designed properly, due to the lack of evidence-based treatment to date for this particular patient group.

A search in the surge of treatment for COVID-19 patients: A narrative literature review

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 822-831
Author(s):  
Sridevi Ugrappa ◽  
Ajay Jain ◽  
Akshay Bhargava ◽  
Neeraj Kumar Fuloria ◽  
Shivkanya Fuloria
Keyword(s):  
Immune Therapy ◽  
Treatment Strategies ◽  
Signs And Symptoms ◽  
Treatment Modalities ◽  
Evidence Based ◽  
Evidence Based Treatment ◽  
Pubmed Search ◽  
Blood Purification Therapy ◽  
Narrative Literature ◽  
Narrative Literature Review

Today, our understanding towards COVID-19 pandemic is that it is contagious and based on the of the virus, the signs and symptoms of this viral resemble the viral infectionlike Severe Acute-Respiratory (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV). Currently, documented vaccines or drugs are not available for the treatment of COVID-19, SARS-CoV-2 viral infection. The main objective of this article is to compile the available literature on the treatment modalities for COVID-19, currently being advocated. Furthermore, there is no time to wait for evidence-based treatment, hence in such a scenario; an attempt has been made to collect the available scientific literature and understand the treatment of the disease with this insight. A MEDLINE-PUBMED search was performed in the surge of the treatment strategies for COVID-19 using the keywords &quot;COVID-19&quot;, &quot;&quot;, &quot;novel &quot;, &quot;treatment of &quot; and &quot;therapies&quot;. We have reviewed the multiple articles from recently published literature and various proofs from up-to-date journals. Based on the reviewed literature, various categories of drugs are under trial or have been tried for the treatment of infection, which are as medications (anti-viral agents, and , ACE-2 inhibitors, etc.), immune therapy, traditional Chinese medicine, plasma exchange therapy, and blood purification therapy, etc. We attempted to go through the literature available for the treatment of COVID-19 and tried to compile it all together. Still, clinical trials are under process, and there are no evidence-based treatment strategies available to manage the cases of COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document